Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: Possible relevance to chronic fatigue syndrome

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 385-387

  Clemons, Anthony ^a,b   Vasiadi, Magdalini ^a   Kempuraj, Duraisamy ^a,c   Kourelis, Taxiarchis ^a,d   Vandoros, Gregory ^a   Theoharides, Theoharis C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ATOMOXETINE; CALCIUM; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; PROCHLORPERAZINE; SUBSTANCE P; VASCULOTROPIN;

BLOOD BRAIN BARRIER; BRAIN NERVE CELL; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ACTIVATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CHRONIC FATIGUE SYNDROME; CYTOKINE RELEASE; DRUG MECHANISM; FIBROMYALGIA; HUMAN; HUMAN CELL; HYPOTHALAMUS; INFLAMMATION; INTERSTITIAL CYSTITIS; IRRITABLE COLON; LETTER; MAST CELL; PRIORITY JOURNAL; THALAMUS;

AMITRIPTYLINE; CELLS, CULTURED; FATIGUE SYNDROME, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; MAST CELLS; PROCHLORPERAZINE;

EID: 79955622333     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182196e50     Document Type: Letter

References (20)

1. Avellaneda FA, Perz MA, Izquierdo MM, et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry. 2009;9(suppl 1):S1.
2. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol. 2003;17(4):563-574.
3. Pae CU, Marks DM, Patkar AA, et al. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother. 2009;10(10):1561-1570.
4. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004;146:1-12. (Pubitemid 38032950)
5. Theoharides TC, Papaliodis D, Tagen M, et al. Chronic fatigue syndrome, mast cells, and tricyclic antidepressants. J Clin Psychopharmacol. 2005;25(6): 515-520. (Pubitemid 41669041)
6. Pollard H, Bischoff S, Llorens-Cortes C, et al. Histidine decarboxylase and histamine in discrete nuclei of rat hypothalamus and the evidence for mast cells in the median eminence. Brain Res. 1976;118: 509-513.
7. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, et al. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res. 1999;849:1-15.
8. Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563-568. (Pubitemid 39371146)
9. Esposito P, Chandler N, Kandere K, et al. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Therap. 2002;303:1061-1066. (Pubitemid 35424390)
10. Kirshenbaum AS, Akin C, Wu Y, et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res. 2003;27: 677-682. (Pubitemid 36683255)
11. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA. 2009;301(2):198-209.
12. Theoharides TC, Bondy PK, Tsakalos ND, et al. Differential release of serotonin and histamine from mast cells. Nature. 1982;297:229-231. (Pubitemid 12066450)
13. Cai Z, McCaslin PP. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-aspartateYinduced intracellular Ca2+ levels in neuronal culture. Eur J Pharmacol. 1992;219(1): 53-57.
14. Johnson HG, Miller MD. Inhibition of histamine release and ionophore-induced calcium flux in rat mast cells by lidocaine and chlorpromazine. Agents Actions. 1979;9(3):239-243. (Pubitemid 10221123)
15. Peachell PT, Pearce FL. Divalent cation dependence of the inhibition by phenothiazines of mediator release from mast cells. Br J Pharmacol. 1989;97(2): 547-555. (Pubitemid 19142760)
16. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749-786. (Pubitemid 40563184)
17. Theoharides TC, Zang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA. 2010;107: 4448-4453.
18. Natelson BH, Weaver SA, Tseng CL, et al. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin Diagn Lab Immunol. 2005;12(1):52-55.
19. White AT, Light AR, Hughen RW, et al. Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology. 2010;47:615-624.
20. Fletcher MA, Zeng XR, Barnes Z, et al. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med. 2009;7:96.